Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus : Randomized Controlled Trial

Cho, Kyu Yong; Nakamura, Akinobu; Oba-Yamamoto, Chiho; Tsuchida, Kazuhisa; Yanagiya, Shingo; Manda, Naoki; Kurihara, Yoshio; Aoki, Shin; Atsumi, Tatsuya; Miyoshi, Hideaki

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus : Randomized Controlled Trial

Cho, Kyu Yong; Nakamura, Akinobu; Oba-Yamamoto, Chiho et al.

Diabetes & Metabolism Journal, 2019, 44(4), 532-541

Permalink : https://hdl.handle.net/2115/78817

このアイテムのアクセス数:518件（2026-04-06 18:50 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.4093/dmj.2019.0093			4

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/78817
タイトル	Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus : Randomized Controlled Trial
著者	Cho, Kyu Yong ; Nakamura, Akinobu ; Oba-Yamamoto, Chiho ; Tsuchida, Kazuhisa ; Yanagiya, Shingo ; Manda, Naoki ; Kurihara, Yoshio ; Aoki, Shin ; Atsumi, Tatsuya ; Miyoshi, Hideaki
著者名 Cho, Kyu Yong
e-Rad_Researcher 70552420 著者名 Nakamura, Akinobu
著者名 Oba-Yamamoto, Chiho
著者名 Tsuchida, Kazuhisa
著者名 Yanagiya, Shingo
著者名 Manda, Naoki
著者名 Kurihara, Yoshio
著者名 Aoki, Shin
e-Rad_Researcher 20301905 著者名 Atsumi, Tatsuya
e-Rad_Researcher 30360902 著者名 Miyoshi, Hideaki
言語	英語
キーワード	Diabetes mellitus, type 2
	Hypoglycemia
	Insulin degludec
	Insulin degludec, insulin aspart drug combination
	Randomized controlled trial
発行日	2019
出版者	Korean Diabetes Association
収録物名	Diabetes & Metabolism Journal
巻(号)	44(4)
ページ	532-541
抄録	Background: To explore the efficacy and safety of switching from once-daily basal insulin therapy to once-daily pre-meal injection insulin degludec/insulin aspart (IDegAsp) with respect to the glycemic control of participants with type 2 diabetes mellitus (T2DM). Methods: In this multicenter, open-label, prospective, randomized, parallel-group comparison trial, participants on basal insulin therapy were switched to IDegAsp (IDegAsp group; n=30) or continued basal insulin (Basal group; n=29). The primary endpoint was the superiority of IDegAsp in causing changes in the daily blood glucose profile, especially post-prandial blood glucose concentration after 12 weeks. Results: Blood glucose concentrations after dinner and before bedtime were lower in the IDegAsp group, and the improvement in blood glucose before bedtime was significantly greater in the IDegAsp group than in the Basal group at 12 weeks (−1.7±3.0 mmol/L vs. 0.3±2.1 mmol/L, P<0.05). Intriguingly, glycemic control after breakfast was not improved by IDegAsp injection before breakfast, in contrast to the favorable effect of injection before dinner on blood glucose after dinner. Glycosylated hemoglobin significantly decreased only in the IDegAsp group (58 to 55 mmol/mol, P<0.05). Changes in daily insulin dose, body mass, and recorded adverse effects, including hypoglycemia, were comparable between groups. Conclusion: IDegAsp was more effective than basal insulin at reducing blood glucose after dinner and before bedtime, but did not increase the incidence of hypoglycemia. Switching from basal insulin to IDegAsp does not increase the burden on the patient and positively impacts glycemic control in patients with T2DM.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial 4.0 International
PISSN	2233-6079
EISSN	2233-6087
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.4093/dmj.2019.0093